AI For Drug Discovery: Weekly News 🍈
🥎 Qubit Pharmaceuticals and Sorbonne University presented FeNNix-Bio1
Qubit Pharmaceuticals in partnership with Sorbonne University developed the world’s most advanced quantum AI model to unlock an entirely 🆕 range of therapeutics at a fraction of the time and cost of current drug discovery efforts (Sorbonne University And Qubit Pharmaceuticals Unveil Powerful Quantum AI Model For Medical Discovery).
The quantum AI model developed is capable of modeling and simulating the behavior of molecules with a level of precision and computational speed never before achieved.
FeNNix-Bio1, is a quantum AI foundation model that simulates molecular behavior with unprecedented accuracy and efficiency.
Unlike previous models, FeNNix-Bio1 can model dynamic molecular interactions, such as covalent drug binding and protein flexibility, enabling in silico design of complex therapies for diseases like cancer.
The scalable model extends beyond pharmaceuticals to broader chemistry applications, including industrial enzymes, green chemistry, and quantum data-driven molecular simulation, marking a step toward automated molecular design.
🥎 J&J launches the Polyphonic AI Fund for Surgery with Nvidia and AWS
On June 25, 2025, Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, launched the Polyphonic™ AI Fund for Surgery to help develop AI solutions that solve challenges before, during, and after surgery (Johnson & Johnson Launches the Polyphonic™ AI Fund for Surgery to Advance Data-Driven Healthcare) by offering up to 💲1️⃣0️⃣0️⃣K and tech support to startups and researchers building AI tools for surgical care. Joined by a coalition of companies including NVIDIA and Amazon Web Services (AWS), the initiative builds on the company’s work to advance AI that will help redefine modern surgical practices and improve patient outcomes.